A detailed history of Td Waterhouse Canada Inc. transactions in Akebia Therapeutics, Inc. stock. As of the latest transaction made, Td Waterhouse Canada Inc. holds 90,618 shares of AKBA stock, worth $166,737. This represents 0.0% of its overall portfolio holdings.

Number of Shares
90,618
Previous 90,553 0.07%
Holding current value
$166,737
Previous $90.2 Million 27.4%
% of portfolio
0.0%
Previous 0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$0.94 - $1.55 $61 - $100
65 Added 0.07%
90,618 $115 Million
Q2 2024

Nov 12, 2024

BUY
$0.86 - $1.63 $43,000 - $81,500
50,000 Added 123.3%
90,553 $90.2 Million
Q2 2023

Nov 13, 2023

BUY
$0.51 - $1.43 $19,890 - $55,770
39,000 Added 2511.27%
40,553 $45.7 Million
Q1 2022

Nov 13, 2023

BUY
$0.72 - $2.93 $188 - $767
262 Added 20.29%
1,553 $1.26 Million
Q4 2021

Nov 13, 2023

BUY
$2.26 - $3.34 $2,917 - $4,311
1,291 New
1,291 $3.87 Million

Others Institutions Holding AKBA

About Akebia Therapeutics, Inc.


  • Ticker AKBA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 183,848,992
  • Market Cap $338M
  • Description
  • Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) ...
More about AKBA
Track This Portfolio

Track Td Waterhouse Canada Inc. Portfolio

Follow Td Waterhouse Canada Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Td Waterhouse Canada Inc., based on Form 13F filings with the SEC.

News

Stay updated on Td Waterhouse Canada Inc. with notifications on news.